- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00507169
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
June 7, 2011 updated by: Salvat
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
Study Overview
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients suffering from OAB for at least 6 months prior to inclusion
Exclusion Criteria:
- Pregnant and breastfeeding women
- Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2007
Study Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
July 25, 2007
First Submitted That Met QC Criteria
July 25, 2007
First Posted (Estimate)
July 26, 2007
Study Record Updates
Last Update Posted (Estimate)
June 8, 2011
Last Update Submitted That Met QC Criteria
June 7, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 40776ORII/05IA01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder (OAB)
-
Stimvia s.r.o.CompletedOveractive Bladder (OAB) | Failed Any OAB PharmacotherapyCzechia
-
Astellas Pharma Singapore Pte. Ltd.CompletedOveractive Bladder (OAB)Korea, Republic of, Australia
-
Jeil Pharmaceutical Co., Ltd.CompletedOveractive Bladder(OAB)Korea, Republic of
-
NovartisProcter and GambleCompletedOveractive Bladder (OAB)United States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Astellas Pharma Singapore Pte. Ltd.CompletedOveractive Bladder (OAB)Korea, Republic of, Australia
-
National and Kapodistrian University of AthensCompletedOveractive Bladder (OAB)Greece
Clinical Trials on SVT-40776
-
Tel-Aviv Sourasky Medical CenterCompletedAtrial FibrillationIsrael
-
Richard KobzaCompletedSymptomatic Supraventricular Tachycardia
-
Bezmialem Vakif UniversityRecruiting
-
KK Women's and Children's HospitalActxa Pte LtdCompletedBlood Glucose, High | Blood Glucose, LowSingapore
-
Abbott Medical DevicesCompleted
-
GWT-TUD GmbHCompletedSuperficial Vein ThrombosisGermany
-
SalvatCompleted